Schizophrenia News

The Pediatric Advisory Committee of the FDA met Tuesday to review data for numerous drugs to determine their safety for pediatric populations.

The FDA has determined that the review of a study to examine the cause of elevated levels of injectable Zyprexa Relprevv in two patients who died to be inconclusive, according to an FDA MedWatch safety announcement.

The British Psychological Society’s report, Understanding Psychosis and Schizophrenia, was recently released in the United States and highlights ways experts can understand and treat patients with psychosis.

Symptoms of psychosis spectrum in youths are associated with executive circuit hypoactivation during working memory and with amygdala hyperactivation when patients process threatening emotional expressions, according to data.

Patients with 22q11.2 deletion syndrome have an increased risk for developing schizophrenia, according to researchers.

Cognitive behavioral therapy may reduce a thinking style of worry – a contributory cause of paranoia, according to Daniel Freeman, PhD.

Fewer than half of inmates who reported being on medication on admission were administered medications in prison, according to a recent analysis.

Patients who underwent first-episode services for schizophrenia or schizoaffective disorder required fewer hospitalizations and had greater vocational functioning compared with those administered usual care, according to study data.

Phase 3 data indicate that cariprazine was safe and efficacious in the prevention of relapse in patients with schizophrenia, according to a press release issued by Actavis.

The FDA has granted priority review status for the new drug application for Janssen’s three-month atypical antipsychotic, paliperidone palmitate, for the treatment of schizophrenia, according to a press release.